Clinical Trials Logo

Disease clinical trials

View clinical trials related to Disease.

Filter by:

NCT ID: NCT03079817 Completed - Parkinson Disease Clinical Trials

Proprioception and Meditation

Start date: January 17, 2017
Phase: N/A
Study type: Interventional

In past work is has been shown that yoga can be as effective as a standard balance or Tai Chi protocol; however, there is an inability to distinguish between the mind and body contributions of yoga training. This study will compare an accepted proprioceptive training program to a meditation program which concentrates on body awareness in individuals with Parkinson's disease.

NCT ID: NCT03078075 Completed - Clinical trials for Methamphetamine Use Disorder

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

ADAPT-2
Start date: May 5, 2017
Phase: Phase 3
Study type: Interventional

This is a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of extended-release naltrexone plus bupropion as a combination pharmacotherapy for methamphetamine use disorder. Participants will be randomly assigned to the active medication combination (AMC) group or matching placebo group and will receive medications over the course of 12 weeks. Follow-ups will occur in weeks 13 and 16.

NCT ID: NCT03077919 Completed - Clinical trials for PostTraumatic Stress Disorder

Effectiveness and Acceptability of Stellate Ganglion Block for Posttraumatic Stress Disorder Symptoms - Effectiveness

Start date: May 25, 2016
Phase: N/A
Study type: Interventional

This is a multisite, randomized, blinded, sham-procedure-controlled study to evaluate the efficacy of right-sided stellate ganglion block (SGB) on the acute symptomatology of Post traumatic Stress Disorder (PTSD), evaluated by the Clinician-Administered PTSD Scale (CAPS-5) clinical interview at pre-treatment and at 8 weeks. This entry describes the effectiveness study.The acceptability study is described in a separate entry.

NCT ID: NCT03072823 Completed - Clinical trials for Cardiovascular Diseases

Omega-3 Polyunsaturated Fatty Acids on Major Depressive Disorder in Patients With Cardiovascular Diseases

Start date: January 27, 2016
Phase: N/A
Study type: Interventional

N-3 polyunsaturated fatty acids(N-3 PUFAs) is important in balancing the immune function and physical health by reducing membrane arachidonic acid (AA) and prostaglandin E2 (PGE2) synthesis, which might be linked to the somatic manifestations physical morbidity, such as Cardiovascular disease in depression. n-3 polyunsaturated fatty acids appears to be a promising treatment that is safe, beneficial to patients with Cardiovascular disease and depression. In this proposal, investigators aim the test the hypothesis that n-3 polyunsaturated fatty acids will be more effective than placebo in treating Cardiovascular disease patients with major depression after 12 weeks of intervention.

NCT ID: NCT03072264 Completed - Clinical trials for Generalized Anxiety Disorder

Randomized Clinical Trial of a Mindfulness Based Intervention in Generalized Anxiety Disorder

Start date: October 2016
Phase: N/A
Study type: Interventional

The literature suggests that Mindfulness Based Intervention may be effective in the treatment of anxiety symptoms. The objective of this study is to compare the clinical effectiveness of a Mindfulness Based Intervention - the Mind in Body Training (MBT) - with a selective serotonin reuptake inhibitor (Fluoxetine) and an active control group (Quality of Life) through different biological and clinical outcomes, as well as evaluate some possible mechanisms of treatment response. Methods: it is a three armed randomized, controlled clinical trial. Participants with General Anxiety Disorder will be recruited. A community sample of 192 participants will be randomly allocated to the MBT, Fluoxetine or Quality of Life Group. Instruments measuring anxiety, worry and meta-worry symptoms, quality of life, acceptance and self-compassion, mindfulness, rumination and emotion regulation will be applied. The patients will be submitted to Error Related Negativity (ERN) and Heart Rate Variability (HRV) measures. The primary outcome is the effectiveness of MBT compared with Fluoxetine and Quality of Life Group in symptomatic outcomes. The secondary outcome are the effectiveness os these interventions in emotional regulation process and biological measures (ERN and HRV), and the evaluation of BMT mechanisms through possible mediation of treatment response for emotional processes like mindfulness, acceptance and self-compassion, biological changes (ERN and HRV), and metacognition.

NCT ID: NCT03067506 Completed - Clinical trials for Major Depressive Disorder

Cognitive and Mood Assessment Data in Major Depressive Disorder Using Digital Wearable Technology

Start date: March 1, 2017
Phase:
Study type: Observational

The purpose of this study was to evaluate the feasibility and compliance with a novel method for assessing mood and cognition in participants with major depressive disorder (MDD).

NCT ID: NCT03066310 Completed - Bladder Cancer Clinical Trials

Urine-DNA Biomarkers in Detecting Bladder Cancer

Start date: January 17, 2017
Phase:
Study type: Observational

DNA biomarkers in urine are important diagnostic and prognostic indicators for bladder cancer. Many genetic alterations have been identified in the urinary DNA. However, not all bladder tumors harbor mutations in the most commonly altered oncogenes. Thus, to reach satisfactory sensitivity and specificity a new diagnostic test should include multiple biomarkers. The investigators will conduct a prospective evaluation of a panel of mutations in urine-DNA test for the detection of urothelial bladder carcinoma in patients with gross hematuria for cystoscope.

NCT ID: NCT03065192 Completed - Parkinson's Disease Clinical Trials

Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

Start date: May 11, 2017
Phase: Phase 1
Study type: Interventional

Safety and efficacy of AADC gene transfer in participants with Parkinson's disease.

NCT ID: NCT03065114 Completed - Fertility Disorders Clinical Trials

Retrospective Study on Clinical Results of Preimplantation Genetic Screening at Different Embryo Stage

Start date: December 1, 2014
Phase: N/A
Study type: Observational

Preimplantational genetic screen (PGS) is tool for diagnosis of embryo chromosome abnormality before transfer. Under this tool, patients with a family history of genetic disease or special genetic disease could avoid to produce chromosomal abnormalities of the next pregnant. This study is a retrospective study, data collection from 2001 Jan. to 2015. Nov. Patients underwent PGS and data including the couples age, infertility factors, stimulation protocols, medicine records, embryo quality records and blood tests were collected in this study. Analysis the relationship between outcomes of PGS, clinical outcomes and embryo quality is performed and further to find a diagnosis reference for clinical care.

NCT ID: NCT03064048 Completed - Urea Cycle Disorder Clinical Trials

Nitric Oxide Supplementation on Neurocognitive Functions in Patients With ASLD

Start date: September 15, 2017
Phase: N/A
Study type: Interventional

This is a study involving a dietary supplement. Patients with argininosuccinate lyase deficiency (ASLD) will be randomly assigned to receive either a nitric oxide dietary supplement or placebo for 24 weeks, and then crossed-over to receive the other treatment for 24 weeks. The investigators will assess the effects of the supplement in domains of general cognition, memory, executive functioning, and fine motor functioning in individuals with ASLD.